Characterization of a membrane-active anti-tumor agent, UA8967

Robert T Dorr, Betty K. Samulitis, Lee Wisner, Haiyong Han, Yu Zhao, Paul Beroza, Komath Damodaran, Suzu Igarashi, Terry H Landowski, Daniel D. Von Hoff

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Deletions or mutations in the tumor suppressor gene DPC4 (deleted in pancreatic carcinoma locus 4) are common in colon and pancreatic cancers. Using the Target-related Affinity Profiling (TRAP) chemical library screening method, a novel agent, UA8967, was selected for further studies because it showed greater potency in DPC4-deleted HCT-116 colon cancer cells. Cytotoxicity studies in six pancreatic cancer cell lines (MiaPaca-2, Panc-1, BxPC3, CF-PAC1, AsPC1, and T3M4), one normal human pancreatic ductal epithelial line (HPDE-6) and the HCT-116 DPC4(+/+) and HCT-116 DPC4(-/-) colon cancer cells showed IC 50s ranging from 12-61 μM for exposure times of 72 h. Analysis of schedule dependence showed no advantage for long drug exposure times. There was also no selective inhibition of DNA, RNA or protein synthesis after exposure to UA8967. At 24-48 h, there was an accumulation of cells in G0/G 1-phase and a proportionate reduction in S-phase cells. Within 1-6 h of exposure, cells were found to undergo an autophagic response, followed at 24 h by a low level of caspase-independent apoptosis with some necrosis. Because of the relatively non-specific mechanistic effects of UA8967, plasma membrane viability was evaluated using uptake of trypan blue and Sytox® Green dyes, and leakage of LDH. There was a dose dependent increase in Sytox® Green staining, trypan blue uptake and LDH leakage with increasing concentrations of UA8967, suggesting that UA8967 is affecting the plasma membrane. The DPC4(-/-) cells were more sensitive to UA8967 but not to DMSO, suggesting a drug-specific effect on cell membrane integrity.

Original languageEnglish (US)
Pages (from-to)576-586
Number of pages11
JournalInvestigational New Drugs
Volume31
Issue number3
DOIs
StatePublished - Jun 2013

Fingerprint

Membranes
Colonic Neoplasms
Neoplasms
Trypan Blue
Cell Membrane
Pancreatic Neoplasms
Small Molecule Libraries
Sequence Deletion
Caspases
Dimethyl Sulfoxide
Tumor Suppressor Genes
S Phase
Pharmaceutical Preparations
3-((4-benzylpiperazino)methyl)-1H-indole
Appointments and Schedules
Necrosis
Coloring Agents
Pancreatic Carcinoma
RNA
Apoptosis

Keywords

  • Autophagy
  • DPC4
  • Membrane integrity
  • SMAD4
  • TRAP
  • UA8967

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)
  • Oncology

Cite this

Dorr, R. T., Samulitis, B. K., Wisner, L., Han, H., Zhao, Y., Beroza, P., ... Von Hoff, D. D. (2013). Characterization of a membrane-active anti-tumor agent, UA8967. Investigational New Drugs, 31(3), 576-586. https://doi.org/10.1007/s10637-012-9901-z

Characterization of a membrane-active anti-tumor agent, UA8967. / Dorr, Robert T; Samulitis, Betty K.; Wisner, Lee; Han, Haiyong; Zhao, Yu; Beroza, Paul; Damodaran, Komath; Igarashi, Suzu; Landowski, Terry H; Von Hoff, Daniel D.

In: Investigational New Drugs, Vol. 31, No. 3, 06.2013, p. 576-586.

Research output: Contribution to journalArticle

Dorr, RT, Samulitis, BK, Wisner, L, Han, H, Zhao, Y, Beroza, P, Damodaran, K, Igarashi, S, Landowski, TH & Von Hoff, DD 2013, 'Characterization of a membrane-active anti-tumor agent, UA8967', Investigational New Drugs, vol. 31, no. 3, pp. 576-586. https://doi.org/10.1007/s10637-012-9901-z
Dorr, Robert T ; Samulitis, Betty K. ; Wisner, Lee ; Han, Haiyong ; Zhao, Yu ; Beroza, Paul ; Damodaran, Komath ; Igarashi, Suzu ; Landowski, Terry H ; Von Hoff, Daniel D. / Characterization of a membrane-active anti-tumor agent, UA8967. In: Investigational New Drugs. 2013 ; Vol. 31, No. 3. pp. 576-586.
@article{24c2fe52a5d44206b739ccbb9d2d5ab5,
title = "Characterization of a membrane-active anti-tumor agent, UA8967",
abstract = "Deletions or mutations in the tumor suppressor gene DPC4 (deleted in pancreatic carcinoma locus 4) are common in colon and pancreatic cancers. Using the Target-related Affinity Profiling (TRAP) chemical library screening method, a novel agent, UA8967, was selected for further studies because it showed greater potency in DPC4-deleted HCT-116 colon cancer cells. Cytotoxicity studies in six pancreatic cancer cell lines (MiaPaca-2, Panc-1, BxPC3, CF-PAC1, AsPC1, and T3M4), one normal human pancreatic ductal epithelial line (HPDE-6) and the HCT-116 DPC4(+/+) and HCT-116 DPC4(-/-) colon cancer cells showed IC 50s ranging from 12-61 μM for exposure times of 72 h. Analysis of schedule dependence showed no advantage for long drug exposure times. There was also no selective inhibition of DNA, RNA or protein synthesis after exposure to UA8967. At 24-48 h, there was an accumulation of cells in G0/G 1-phase and a proportionate reduction in S-phase cells. Within 1-6 h of exposure, cells were found to undergo an autophagic response, followed at 24 h by a low level of caspase-independent apoptosis with some necrosis. Because of the relatively non-specific mechanistic effects of UA8967, plasma membrane viability was evaluated using uptake of trypan blue and Sytox{\circledR} Green dyes, and leakage of LDH. There was a dose dependent increase in Sytox{\circledR} Green staining, trypan blue uptake and LDH leakage with increasing concentrations of UA8967, suggesting that UA8967 is affecting the plasma membrane. The DPC4(-/-) cells were more sensitive to UA8967 but not to DMSO, suggesting a drug-specific effect on cell membrane integrity.",
keywords = "Autophagy, DPC4, Membrane integrity, SMAD4, TRAP, UA8967",
author = "Dorr, {Robert T} and Samulitis, {Betty K.} and Lee Wisner and Haiyong Han and Yu Zhao and Paul Beroza and Komath Damodaran and Suzu Igarashi and Landowski, {Terry H} and {Von Hoff}, {Daniel D.}",
year = "2013",
month = "6",
doi = "10.1007/s10637-012-9901-z",
language = "English (US)",
volume = "31",
pages = "576--586",
journal = "Investigational New Drugs",
issn = "0167-6997",
publisher = "Kluwer Academic Publishers",
number = "3",

}

TY - JOUR

T1 - Characterization of a membrane-active anti-tumor agent, UA8967

AU - Dorr, Robert T

AU - Samulitis, Betty K.

AU - Wisner, Lee

AU - Han, Haiyong

AU - Zhao, Yu

AU - Beroza, Paul

AU - Damodaran, Komath

AU - Igarashi, Suzu

AU - Landowski, Terry H

AU - Von Hoff, Daniel D.

PY - 2013/6

Y1 - 2013/6

N2 - Deletions or mutations in the tumor suppressor gene DPC4 (deleted in pancreatic carcinoma locus 4) are common in colon and pancreatic cancers. Using the Target-related Affinity Profiling (TRAP) chemical library screening method, a novel agent, UA8967, was selected for further studies because it showed greater potency in DPC4-deleted HCT-116 colon cancer cells. Cytotoxicity studies in six pancreatic cancer cell lines (MiaPaca-2, Panc-1, BxPC3, CF-PAC1, AsPC1, and T3M4), one normal human pancreatic ductal epithelial line (HPDE-6) and the HCT-116 DPC4(+/+) and HCT-116 DPC4(-/-) colon cancer cells showed IC 50s ranging from 12-61 μM for exposure times of 72 h. Analysis of schedule dependence showed no advantage for long drug exposure times. There was also no selective inhibition of DNA, RNA or protein synthesis after exposure to UA8967. At 24-48 h, there was an accumulation of cells in G0/G 1-phase and a proportionate reduction in S-phase cells. Within 1-6 h of exposure, cells were found to undergo an autophagic response, followed at 24 h by a low level of caspase-independent apoptosis with some necrosis. Because of the relatively non-specific mechanistic effects of UA8967, plasma membrane viability was evaluated using uptake of trypan blue and Sytox® Green dyes, and leakage of LDH. There was a dose dependent increase in Sytox® Green staining, trypan blue uptake and LDH leakage with increasing concentrations of UA8967, suggesting that UA8967 is affecting the plasma membrane. The DPC4(-/-) cells were more sensitive to UA8967 but not to DMSO, suggesting a drug-specific effect on cell membrane integrity.

AB - Deletions or mutations in the tumor suppressor gene DPC4 (deleted in pancreatic carcinoma locus 4) are common in colon and pancreatic cancers. Using the Target-related Affinity Profiling (TRAP) chemical library screening method, a novel agent, UA8967, was selected for further studies because it showed greater potency in DPC4-deleted HCT-116 colon cancer cells. Cytotoxicity studies in six pancreatic cancer cell lines (MiaPaca-2, Panc-1, BxPC3, CF-PAC1, AsPC1, and T3M4), one normal human pancreatic ductal epithelial line (HPDE-6) and the HCT-116 DPC4(+/+) and HCT-116 DPC4(-/-) colon cancer cells showed IC 50s ranging from 12-61 μM for exposure times of 72 h. Analysis of schedule dependence showed no advantage for long drug exposure times. There was also no selective inhibition of DNA, RNA or protein synthesis after exposure to UA8967. At 24-48 h, there was an accumulation of cells in G0/G 1-phase and a proportionate reduction in S-phase cells. Within 1-6 h of exposure, cells were found to undergo an autophagic response, followed at 24 h by a low level of caspase-independent apoptosis with some necrosis. Because of the relatively non-specific mechanistic effects of UA8967, plasma membrane viability was evaluated using uptake of trypan blue and Sytox® Green dyes, and leakage of LDH. There was a dose dependent increase in Sytox® Green staining, trypan blue uptake and LDH leakage with increasing concentrations of UA8967, suggesting that UA8967 is affecting the plasma membrane. The DPC4(-/-) cells were more sensitive to UA8967 but not to DMSO, suggesting a drug-specific effect on cell membrane integrity.

KW - Autophagy

KW - DPC4

KW - Membrane integrity

KW - SMAD4

KW - TRAP

KW - UA8967

UR - http://www.scopus.com/inward/record.url?scp=84879114657&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84879114657&partnerID=8YFLogxK

U2 - 10.1007/s10637-012-9901-z

DO - 10.1007/s10637-012-9901-z

M3 - Article

C2 - 23179338

AN - SCOPUS:84879114657

VL - 31

SP - 576

EP - 586

JO - Investigational New Drugs

JF - Investigational New Drugs

SN - 0167-6997

IS - 3

ER -